Allergy Shot Side Effect Rates: How Often Each Reaction Actually Occurs
How often allergy shots cause side effects depends on which side effect you mean. Local injection-site reactions occur in 26-86% of patients. Systemic reactions affect 0.1-0.2% of visits — about 10.2 per 10,000 — with 74% being mild Grade 1 events. Anaphylaxis occurs in approximately 1 per 160,000 visits. Fatal reactions have fallen to 1 per 9 million visits in modern practice. Every rate below includes its study denominator.
9 peer-reviewed sources
Local allergy shot reactions occur in 26-86% of patients; systemic reactions in 0.1-0.2% of injection visits. Anaphylaxis is rare at 1 per 160,000 visits and fatal reactions rarer still at 1 per 9 million visits.
Key facts
A 2026 retrospective cohort of 2,897 patients found the sublingual route sustained treatment over multiple years in a real-world setting; it is observational, so it describes what happened to those patients rather than proving one route beats another.
Why Allergy Shot Side Effect Rates Vary So Widely — and What the Real Numbers Are
The first challenge with allergy shot side effect statistics is that rates vary dramatically depending on how the side effect is defined, how it is measured, and which population was studied. Local reaction rates quoted in different publications range from 26% to 86% of patients — a three-fold difference driven entirely by whether researchers used a 2.5 cm threshold, a palm-size threshold, or any visible wheal. Understanding the denominator and measurement method is as important as the rate itself.
The primary source for all systemic reaction data in this page is the AAAAI/ACAAI National Surveillance Study of Allergen Immunotherapy — one of the most comprehensive post-market safety surveillance programs in medicine, tracking more than 54 million injection visits across thousands of US practices from 2008-2017 (Bernstein 2010; Epstein 2011-2019). Three US fatality surveys (Lockey 1987; Reid 1993; Bernstein 2004) provide the historical reference points for fatal reaction trends over time. Complementing that surveillance, a large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) reported a systemic reaction rate of just 0.16% per patient across 23,614 patients giving 2,021,600 injections, with no fatalities — lower than the 3% to 14% typically reported with office-based shots.
Before starting immunotherapy, knowing which allergens you are sensitized to — and at what degree — helps your allergist predict where you fall on the risk spectrum. Patients with very high specific IgE concentrations for their target allergens carry a different per-visit risk profile than those with moderate sensitization. At-home allergy testing through options like Curex provides the comprehensive sensitization map across 40+ allergens that makes this individualized risk assessment possible.
Allergy shot side effect rates are well-characterized from 54 million injection visits. The frequency hierarchy runs: local reactions (common), mild systemic reactions (uncommon), severe reactions (rare), fatal reactions (exceedingly rare).
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex at-home allergy shots are clinician-supervised; confirm your current program quote before enrolling.
Join the waitlistCurex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
At-Home Allergy Shots (SCIT) vs SLIT Reaction Rates: A Side-by-Side Data Comparison
The most clinically useful cross-modality rate comparison comes from the Dretzke 2013 indirect meta-analysis (JACI) and the WAO 2013 Position Paper (Canonica, World Allergy Organ J 2014). SCIT and SLIT have meaningfully different systemic reaction frequencies and severity distributions — both are effective disease-modifying options, and understanding these differences helps patients and clinicians choose the modality that best fits the patient. For eligible patients, the shot itself is now available at home through Curex, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector confirmed on hand.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
At-Home Allergy Shots (SCIT) — CurexBest | Significant improvement for many patients with completed therapy | 3-5 years | $3,000-10,000 with insurance | At-home weekly self-injection with Curex; the first dose and each dose change are supervised live in the Virtual Shot Room, with a brief self-observation afterward | Systemic reactions 0.1-0.2% of visits; ~19% of SRs are severe (Dretzke 2013) |
Sublingual Drops (SLIT) | Comparable disease modification for grass, ragweed, and HDM | 3-5 years, daily at home | Lower when clinic visit costs are eliminated | At-home daily dosing; no needles; no commute | Systemic reactions ~0.056% of doses; ~2% of SRs are severe; no confirmed fatalities |
Antihistamines (Daily OTC) | Symptom control only; no disease modification | Ongoing indefinitely | $500-2,000 | Daily pill; no clinic required | Zero injection or IgE-reaction risk; drowsiness possible |
- Efficacy
- Significant improvement for many patients with completed therapy
- Duration
- 3-5 years
- Cost (5yr)
- $3,000-10,000 with insurance
- Convenience
- At-home weekly self-injection with Curex; the first dose and each dose change are supervised live in the Virtual Shot Room, with a brief self-observation afterward
- Safety
- Systemic reactions 0.1-0.2% of visits; ~19% of SRs are severe (Dretzke 2013)
- Efficacy
- Comparable disease modification for grass, ragweed, and HDM
- Duration
- 3-5 years, daily at home
- Cost (5yr)
- Lower when clinic visit costs are eliminated
- Convenience
- At-home daily dosing; no needles; no commute
- Safety
- Systemic reactions ~0.056% of doses; ~2% of SRs are severe; no confirmed fatalities
- Efficacy
- Symptom control only; no disease modification
- Duration
- Ongoing indefinitely
- Cost (5yr)
- $500-2,000
- Convenience
- Daily pill; no clinic required
- Safety
- Zero injection or IgE-reaction risk; drowsiness possible
Patients who want disease-modifying immunotherapy can now get the allergy shot itself at home through Curex — a personalized SCIT serum sterile-compounded to USP <797> standards, with the first injection from each new vial or concentration supervised live in the Virtual Shot Room and a prescribed epinephrine auto-injector confirmed on hand. Financing is program quote required on some plans, and Curex treats the same allergen triggers as clinic shots, without the weekly trip.
Join the waitlistReaction Rates by Category: From Most Common to Rarest
Every rate below is reported with its original study denominator. The most common methodological error in patient-facing content is quoting a rate without specifying whether it is per patient, per injection, per year of treatment, or per practice. All rates here are per injection visit unless explicitly noted otherwise. Rates are organized from most frequent to least frequent — not from least to most severe. This reflects how the data are most honestly presented: the thing most likely to happen to you is the local reaction, not anaphylaxis, and the numbers should communicate that hierarchy clearly. The per-protocol and per-schedule rate differences (conventional vs cluster/rush) are included because they are among the most consequential modifiers of individual risk. Source series: Bernstein 2010 (Year 1; 8.1M visits; Ann Allergy); Epstein 2011 (Year 2; 2,105 timed SRs; Ann Allergy); Epstein 2019 (2008-2016; 54.4M visits; JACI Pract); Bernstein/Epstein 2020 (synthesis; Allergy Asthma Proc). Local reaction rates from James & Bernstein 2017 review, Calabria 2009 LOCAL Study, and Roy 2007 multicenter study.
Local reactions are the most frequent side effect of allergy shots by an order of magnitude. Per-patient prevalence: 26-86% of SCIT recipients across published cohorts (James & Bernstein 2017 review). This wide range exists because different studies used different size thresholds: 2.5 cm erythema, palm-size induration, or any visible wheal. For large local reactions (LLR) specifically, the LOCAL Study (Calabria, Coop, Tankersley 2009, JACI; 9,678 injections, n=360) reported 0.4% of injections; the Roy 2007 multicenter study (1,108,621 injections) found 5.3% of injections in non-systemic-reactor controls and 19.5% in systemic-reactor patients; an Ozdemir pediatric cohort (19,562 injections) found 0.2%. The 13-fold range between lowest and highest LLR rates is almost entirely explained by definition differences, not biological variation.
Ice, antihistamine. Report LLRs to allergist before next injection. No emergency action needed for local-only symptoms regardless of size.
Grade 1 systemic reactions — affecting only one organ system (cutaneous, upper-respiratory, or conjunctival) — are the most common type of systemic event. From the Year 1 AAAAI/ACAAI surveillance dataset: 8,502 systemic reactions across 8.1 million injection visits = 10.5 per 10,000 overall; of those, 74% were Grade 1 = approximately 7.6 per 10,000 visits, or 1 in every 1,300 injection appointments. Mild SR rate per patient per year: approximately 0.7% (Bernstein/Epstein 2020). Conventional build-up SR rate: approximately 0.2% per injection (Cox 2011 Practice Parameter). Grade 1 events resolve with antihistamines and extended observation period.
Take an antihistamine and contact your care team right away; use your prescribed epinephrine auto-injector if symptoms progress. On a Virtual Shot Room–supervised dose your allergist directs treatment live. Stay observed until symptoms are clearly resolving before resuming activity.
Grade 2 (multiple organ systems or lower-respiratory symptoms): approximately 2.3 per 10,000 visits (23% of systemic reactions, Bernstein 2010). Grade 3 (severe bronchospasm with 40%+ PEF/FEV1 drop or laryngeal edema): approximately 0.3 per 10,000 visits (3% of SRs) — roughly 1 per 300,000 injection visits. Cluster/rush protocol rates are approximately 3x higher: Tversky 2022 (JACI; n=91) found 0.69% per injection for standard vs 2.29% for cluster (IRR 3.3; 95% CI 1.5-7.3). A multicenter cluster cohort (Ann Allergy 2011; n=441) reported 10.9% per-patient SR rate including 11% Grade 3 and 2% Grade 4. Delayed-onset SRs (>30 minutes post-injection): 15% of all systemic reactions across two surveillance periods (Epstein 2011; Epstein 2019).
Immediate IM epinephrine by clinic staff. 911 called for Grade 3. Extended observation minimum 4-8 hours. Allergist reviews protocol before next injection.
Grade 4 anaphylaxis (respiratory failure or hypotension): approximately 1 per 160,000 injection visits, derived from Bernstein/Epstein 2020 (Allergy Asthma Proc; synthesis of Year 1-10 surveillance). Near-fatal reactions: approximately 5.4 per million injections (Amin, Liss, Bernstein 2006, JACI). Fatal reactions: historical trend from 1 per 2.8 million (Lockey 1987; 1945-1984) to 1 per 2 million (Reid 1993; 1985-1989) to 1 per 2.5 million (Bernstein 2004; 1990-2001) to approximately 1 per 9 million (Epstein 2019; 2008-2017). The 3.75-fold improvement in the modern era reflects asthma screening, pollen-season dose reduction, and prompt epinephrine protocols. 88% of confirmed fatalities: uncontrolled asthma (Bernstein 2004). 59% of fatalities: maintenance phase (not just build-up). 41% of historical fatalities: occurred during patient's relevant pollen season (Lockey 1987).
Immediate IM epinephrine, call 911, place supine with legs elevated. Monitor 4-8 hours minimum for biphasic recurrence. Epinephrine first — not antihistamines, not wait-and-see.
When to Worry: Decision Guide
Is the reaction limited to the injection arm only (local redness, swelling, itching)?
Local reaction — 26-86% of patients experience this
Ice, antihistamine. Report LLR to allergist if swelling exceeds quarter size and persists >24 hours.
Systemic reaction — 0.1-0.2% of visits
Treat any symptom outside the injection arm as a possible systemic reaction — use your prescribed epinephrine auto-injector if it progresses, call 911 for severe symptoms, and notify your care team. On a Virtual Shot Room–supervised dose your allergist directs treatment live.
One organ system only OR multiple organ systems / breathing difficulty?
Grade 1 (74% of systemic reactions) — antihistamine, observe
Antihistamine treatment, extended observation. Allergist clears before discharge.
Grade 2+ (26% of systemic reactions) — epinephrine
Immediate IM epinephrine. Do not wait for symptom progression to treat.
Frequently asked questions
What is the exact rate of systemic reactions from allergy shots?
The AAAAI/ACAAI National Surveillance Study — the largest dataset available — reported 8,502 systemic reactions across 8.1 million injection visits in Year 1 (Bernstein 2010, Ann Allergy), giving a rate of approximately 10.5 per 10,000 visits, or 0.1-0.2% of injection appointments. A 2008-2017 synthesis across 54.4 million visits (Epstein 2019, JACI Pract) found consistent rates in the same range. The per-patient annual rate is approximately 0.7% (Bernstein/Epstein 2020). These rates apply to conventional build-up and maintenance schedules. Cluster and rush protocols carry roughly three times higher per-injection systemic reaction rates (Tversky 2022, JACI), which is why accelerated schedules require antihistamine premedication and more intensive monitoring.
How often do allergy shots cause anaphylaxis?
Grade 4 anaphylaxis — defined as respiratory failure with or without loss of consciousness, or hypotension with or without loss of consciousness — occurs at approximately 1 per 160,000 injection visits based on AAAAI/ACAAI surveillance data (Bernstein/Epstein 2020, Allergy Asthma Proc). This translates to roughly 0.00063% of injection visits. For context, across the 8.1 million visits tracked in the Year 1 surveillance study, this rate implies approximately 50 Grade 4 events nationally per year. The rate of near-fatal reactions (requiring hospitalization or intubation but not resulting in death) was estimated at approximately 5.4 per million injections in a separate JACI analysis (Amin, Liss, Bernstein 2006).
Have allergy shot fatalities become rarer over time?
Yes — allergy shot fatal reactions have improved significantly over several decades. Three historical US fatality surveys document the trend: Lockey 1987 (JACI; 1945-1984 data) found approximately 1 per 2.8 million injections; Reid 1993 (JACI; 1985-1989) found approximately 1 per 2 million injections; Bernstein 2004 (JACI; 1990-2001; 41 confirmed fatalities across 3.4 per year average) found approximately 1 per 2.5 million visits. The Epstein 2019 JACI Pract analysis covering 2008-2017 across 54.4 million visits found approximately 1 per 9 million visits — a 3.75-fold improvement from the Bernstein 2004 era. This improvement is attributed to wider adoption of asthma screening before injections, peak-season dose reduction protocols, and Practice Parameter adherence.
Why is the local reaction rate range so wide (26-86%)?
The 26-86% range for local reaction rates in allergy shot patients reflects differences in measurement methodology across studies, not instability in the underlying biology. Studies that counted any visible wheal — including very small reactions indistinguishable from a mosquito bite — report rates toward the upper end of the range. Studies that used a stricter cutoff (such as erythema larger than 2.5 cm) report lower rates. Similarly, how reactions were recorded — patient self-report vs. trained nurse measurement at a fixed time point vs. daily diary cards — introduces additional variation. The Local Study (Calabria 2009, JACI) used standardized 30-minute assessment criteria and a defined measurement protocol, reporting 0.4% of injections for LLR specifically. The take-home message is that local reactions are common at any measurement threshold, but the severity and clinical significance vary considerably.
Are delayed allergy shot reactions common?
Delayed systemic reactions — those beginning more than 30 minutes after the injection — account for approximately 15% of all systemic reactions in two separate AAAAI/ACAAI surveillance analyses (Epstein 2011, Ann Allergy; Epstein 2019, JACI Pract). The delayed proportion is similar across reaction grades: 15% of Grade 1, 10% of Grade 2, and 12.5% of Grade 3 reactions were delayed beyond the 30-minute window (Epstein 2011). A single-center 10-year analysis by Larenas-Linnemann (2017, JACI Pract; 57,102 injections) found a much higher delayed rate of 52.8%, with seven reactions beginning 90 minutes or more post-injection — suggesting the conventional 30-minute window may underestimate delayed risk in some practice settings. This is why patients are advised to self-monitor for symptoms for 2-4 hours after your 30-minute observation window ends.
How much does pollen season affect allergy shot reaction rates?
Pollen season measurably increases allergy shot reaction risk for sensitized patients. Year 3 surveillance data (Epstein 2013, Ann Allergy) found that practices consistently reducing doses during peak pollen season had significantly fewer Grade 2-3 systemic reactions compared to practices that did not (44% vs 65% of events, p=0.04). The biological mechanism is well understood: repeated outdoor allergen exposure during pollen season upregulates tissue mast cells, eosinophils, and adhesion molecules, meaning the same maintenance dose that was well-tolerated in winter can trigger a larger response in April or May. Historical fatality data found that 41% of allergy shot deaths occurred during the patient's relevant pollen season (Lockey 1987, JACI). Standard clinical practice is to reduce maintenance doses by approximately 50% during peak season and gradually return to full maintenance after.
Do recurrent large local reactions predict a higher systemic reaction rate?
This question has evolved beyond the simple 'no' that older guidelines implied. The current evidence is more nuanced. An isolated large local reaction does not reliably predict a systemic reaction at the next visit — the 2011 AAAAI/ACAAI Practice Parameter states this explicitly, citing the LOCAL Study (Calabria 2009) and Tankersley 2000 as supporting evidence. However, a pattern of recurrent large local reactions does identify a higher-risk subset. The REPEAT Study (Calabria 2011, Ann Allergy) found 41.7% of patients with frequent recurrent LLRs experienced at least one systemic reaction during follow-up, versus 10.7% of patients without recurrent LLRs — a 3.9-fold difference. Roy 2007 found LLR rates were four-fold higher in systemic-reactor patients, and about one-third of systemic reactions were preceded by large local reactions. The synthesis: one LLR is not informative; a pattern of recurrent LLRs is.
How do cluster allergy shot reaction rates compare to standard schedules?
Cluster build-up — administering multiple injections per visit to reach maintenance faster — significantly increases per-injection systemic reaction rates compared to conventional schedules. A Johns Hopkins prospective study (Tversky 2022, JACI; n=91) found 0.69% per injection for standard schedules versus 2.29% for cluster (incidence rate ratio 3.3; 95% CI 1.5-7.3). A multicenter cluster cohort (Ann Allergy 2011; n=441) found 10.9% per-patient systemic reaction rate during the accelerated phase, with 11% Grade 3 and 2% Grade 4 reactions. Rush protocols have historically shown even higher rates without premedication, but Portnoy 1994 demonstrated that antihistamine premedication reduced rush SR rates from 73% to 27%. Cluster and rush schedules are appropriate for some patients but require more intensive monitoring protocols and antihistamine premedication.
Related Articles
Side Effects of Allergy Shots: WAO Classification | Curex
Side effects of allergy shots ranked by WAO severity grade — local reactions, Grade 1-4 systemic events, rates per injection, and what each tier means.
Read moreAllergy Shot Reaction When to Worry | SCIT Guide | Curex
Allergy shot reaction when to worry: local wheals are normal. Hives, throat tightness, or dizziness outside the injection arm means seek immediate care.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT retrains the immune system over 3–5 years and is the only disease-modifying allergy treatment; many patients get long-term relief that can persist after treatment.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreAllergy Shots: Complete SCIT Guide for Patients | Curex
Allergy shots (SCIT) reduce symptoms by 33-85% over 3-5 years. Learn how they work, what they cost, and who qualifies for this disease-modifying treatment.
Read moreGet your allergy shots — without the clinic.
Curex at-home shots require a program quote. Confirm what is included in your plan — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
Program quote required · Remaining payments for shipped treatment are collected on cancellation
Curex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.